R Moses, R Slobodniuk, S Boyages, S Colagiuri, W … - Diabetes Care, 1999 - Am Diabetes Assoc I n the US, there are 7 million people with diagnosed type 2 diabetes (1). Within the first 10 years
of diagnosis, mo re than half of all those with type 2 dia- betes take oral hypoglycemic agents
(2). ... Between 1970 and 1995, sulfonylure as we re the only oral antidiabetic agents ... Cited by 215 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org [PDF] RB Goldberg, D Einhorn, CP Lucas, MS Rendell, P … - Diabetes Care, 1998 - Am Diabetes Assoc Repaglinide versus placebo in type 2 diabetes trial was conducted at five US medical cen-
ters. After an initial screening followed by a 2-week washout period, eligible patients were randomized
to receive either repaglin- ide or placebo. Drug doses were adjusted during the first 6 ... Cited by 128 - Related articles - BL Direct - All 5 versions
T Marbury, WC Huang, P Strange, H Lebovitz - Diabetes research and clinical …, 1999 - Elsevier This prospective, 1-year, multicenter, double-blind, randomized, parallel-group study was designed
to show that repaglinide was at least equivalent to glyburide in patients with type 2 diabetes.
Five hundred and seventy-six patients with type 2 diabetes of at least 6 months' duration ... Cited by 131 - Related articles - All 7 versions
BHR Wolffenbuttel, R Landgraf - Diabetes Care, 1999 - Am Diabetes Assoc T ype 2 diabetes is a heterogeneous diso rder characterized by impaire d insulin secretion, diminished
periph- eral insulin action, and increased hepatic glucose production (1,2). The major thera-
peuticgoalsinthesepatients aretooptimize blood glucose control, reduce weight, and no ... Cited by 87 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] P Damsbo, P Clauson, TC Marbury, K Windfeld - Diabetes Care, 1999 - Am Diabetes Assoc Type 2 diabetes is caused by both impai red insulin secretion and dec reased insulin
sensitivity. Although the prevalence of type 2 diabetes varies between diff e rent populations,
the disease has been re po rted to affect more than 3% of the adult population. The pre ... Cited by 113 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] ES Horton, C Clinkingbeard, M Gatlin, J Foley, S … - Diabetes Care, 2000 - Am Diabetes Assoc From the Joslin Diabetes Center (ESH), Boston, Massachusetts; the Idaho Endocrine Specialists
(CC), Boise, Idaho; the Cardiovascular, Metabolic and Endocrine Department (MG, SM), Clinical
Research Divi- sion; and the Biostatistics Division (SS), Novartis Pharmaceuticals, East ... Cited by 206 - Related articles - BL Direct - All 9 versions
J Rosenstock, A Brown, J Fischer, A Jain, T … - Diabetes Care, 1998 - Am Diabetes Assoc T he aim of all strategies for the meta- bolic control of diabetes is to achieve no rmoglycemia.
In patients with type 2 diabetes with milder elevations in fasting plasma glucose, aninitial attempt
to contro l blood glucose is usually undert aken th rough diet, that is, through re stricting ... Cited by 63 - Related articles - BL Direct - All 6 versions
R Landgraf, HJG Bilo, PG Müller - European journal of clinical pharmacology, 1999 - Springer Abstract Objective: To compare the e cacy and safety of repaglinide, a novel oral prandial glucose
regulator, with that of glibenclamide, an oral hypoglycaemic agent, in the treatment of patients
with type 2 diabetes. Methods: This was a 14-week, double-blind, parallel- group trail in ... Cited by 72 - Related articles - All 3 versions
- ►diabetesjournals.org [PDF] P Raskin, L Jovanovic, S Berger, S Schwartz, V … - Diabetes Care, 2000 - Am Diabetes Assoc From the University of Texas Southwest Medical Center (PR), Dallas, Texas; the Sansum Medical
Research Institute (LJ), La Jolla, California; the Chicago Center for Clinical Research (SB),
Chicago, Illinois; the Dia- betes and Glandular Disease Clinic (SS), San Antonio, Texas; ... Cited by 43 - Related articles - BL Direct - All 5 versions
L Jovanovic, G Dailey 3rd, WC Huang, P … - The Journal of …, 2000 - jclinpharm.highwire.org Lois Jovanovic, MD, George Dailey III, MD, Won-Chin Huang, PhD, Poul Strange, MD, PhD, and
Barry J. Goldstein, MD, PhD ... The pathology of glucose intolerance in type 2 dia- ... From Sansum
Medical Research Institute, Santa Barbara, California (Dr. Jovanovic); Scripps Clinic & ... Cited by 67 - Related articles - BL Direct - All 5 versions
